Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Update

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,740,000 shares, a drop of 20.5% from the September 15th total of 2,190,000 shares. Based on an average daily trading volume, of 10,250,000 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Applied DNA Sciences to a “sell” rating in a research note on Tuesday, September 17th.

Hedge Funds Weigh In On Applied DNA Sciences

An institutional investor recently raised its position in Applied DNA Sciences stock. AMH Equity Ltd increased its holdings in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 540,385 shares of the technology company’s stock after buying an additional 170,385 shares during the period. AMH Equity Ltd owned 63.57% of Applied DNA Sciences worth $222,000 as of its most recent SEC filing. Institutional investors own 22.22% of the company’s stock.

Applied DNA Sciences Trading Down 4.8 %

Shares of NASDAQ APDN opened at $0.30 on Tuesday. The stock has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $2.05. Applied DNA Sciences has a 1-year low of $0.29 and a 1-year high of $22.80. The firm has a market cap of $295,500.00, a price-to-earnings ratio of -0.02 and a beta of 0.34.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Thursday, August 8th. The technology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.64) by $1.11. Applied DNA Sciences had a negative return on equity of 138.41% and a negative net margin of 214.42%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.95 million. During the same quarter in the prior year, the company earned ($4.80) EPS. Analysts forecast that Applied DNA Sciences will post -1.8 EPS for the current year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.